External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>AIL reported revenue growth of 12.3% YoY in Q3FY25, slightly ahead of expectations of 8% YoY.</li><li>Abbott’s growth of 12.3% outpaced the IPM's growth of 8.0%.</li><li>An increase in secondary sales and a higher share of Duphalac, Udiliv, and Rybelsus, which reported QoQ growth of 17.1%, 19.4%, and 51% respectively, contributed to the improved market share.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

AIL reported revenue growth of 12.3% YoY in Q3FY25, slightly ahead of expectations of 8% YoY.Abbott’s growth of 12.3% outpaced the IPM's growth of 8.0%.An increase in secondary sales and a higher share of Duphalac, Udiliv, and Rybelsus, which reported QoQ growth of 17.1%, 19.4%, and 51% respectively, contributed to the improved market share.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India Ltd - Outpacing IPM & Sustaining Higher EBITDA Margins

External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>ABB India (ABB) reported muted revenue of INR 29bn, +5% YoY compared to double-digit growth reported in last 14 quarters.</li><li>Note that revenues grew by 19%, 24%, 22% and 20% in CY21, CY22, CY23 and H1CY24 respectively.</li><li>Order inflow for the quarter was INR 34bn, + 11% YoY.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India (ABB) reported muted revenue of INR 29bn, +5% YoY compared to double-digit growth reported in last 14 quarters.Note that revenues grew by 19%, 24%, 22% and 20% in CY21, CY22, CY23 and H1CY24 respectively.Order inflow for the quarter was INR 34bn, + 11% YoY.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India - A Sub-Par Revenue and Order Inflow

<ul><li>Abbott India, a leading pharmaceutical company and subsidiary of Abbott Laboratories, focuses on developing and distributing a diverse range of healthcare products across key therapeutic areas, including gastroenterology, women's health, cardiology, CNS, and others.</li><li>Known for its commitment to innovation, the company offers popular brands such as Digene and Thyronorm.</li><li>With a robust distribution network and adherence to high-quality manufacturing standards, Abbott India plays a significant role in improving healthcare outcomes across the country.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India, a leading pharmaceutical company and subsidiary of Abbott Laboratories, focuses on developing and distributing a diverse range of healthcare products across key therapeutic areas, including gastroenterology, women's health, cardiology, CNS, and others.Known for its commitment to innovation, the company offers popular brands such as Digene and Thyronorm.With a robust distribution network and adherence to high-quality manufacturing standards, Abbott India plays a significant role in improving healthcare outcomes across the country.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Abbott India Ltd. - 28 October 2024

External broker reports(aggregated public sources), Prabhudas Lilladhar

Prabhudas Lilladhar

Prabhudas Lilladher is one of India's leading research based financial services organisation.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Prabhudas Lilladher's research report onABB India We revise our CY24/25E EPS estimates by +16.0%/+21.4% factoring in a robust demand environment and healthy margin improvement.</li><li>ABB India (ABB) reported robust quarterly performance with revenue growing 27.8% YoY and EBITDA margin expanding by 652bps YoY to 18.3%.</li><li>ABB is building a technologically strong portfolio to cater to high growth segments such as data centers, rail &amp; metro and electronics which continue to see good traction.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Prabhudas Lilladher's research report onABB India We revise our CY24/25E EPS estimates by +16.0%/+21.4% factoring in a robust demand environment and healthy margin improvement.ABB India (ABB) reported robust quarterly performance with revenue growing 27.8% YoY and EBITDA margin expanding by 652bps YoY to 18.3%.ABB is building a technologically strong portfolio to cater to high growth segments such as data centers, rail &amp; metro and electronics which continue to see good traction.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India (ABB IN) - Stellar Quarter; Outlook Remains Very Robust

<ul><li>AILreported revenue growth of 7.1% YoY and outpaced the IPM’s growth of 6% in Q4FY24.</li><li>While Chronic growth halved to 6%, Acute therepy segement continued its muted performance in the last quarter.</li><li>The compnay achieved higher sales growth on accoutnt of a change in product mix, and a higher share of the antidiabetics, vitamins, and Hormones which reported YoY growth of 8.3%, 10.8% and 13.3% respectively. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

AILreported revenue growth of 7.1% YoY and outpaced the IPM’s growth of 6% in Q4FY24.While Chronic growth halved to 6%, Acute therepy segement continued its muted performance in the last quarter.The compnay achieved higher sales growth on accoutnt of a change in product mix, and a higher share of the antidiabetics, vitamins, and Hormones which reported YoY growth of 8.3%, 10.8% and 13.3% respectively. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India Ltd - Highest-Ever EBITDA Margins

India

ABB India Limited is a leading technology company specializing in electrification, motion, process automation, and robotics. It provides industrial systems and solutions that optimize power, enhance industrial productivity, and enable a more sustainable future across factories, utilities, rail, and infrastructure. The company was incorporated in 1949 and is headquartered in Bengaluru, Karnataka, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ABB India (ABB IN)

Abbott India Ltd - Outpacing IPM & Sustaining Higher EBITDA Margins

AIL reported revenue growth of 12.3% YoY in Q3FY25, slightly ahead of expectations of 8% YoY. Abbott’s growth of 12.3% outpaced the IPM's growth of...

Axis Direct

ABB India - A Sub-Par Revenue and Order Inflow

Note that revenues grew by 19%, 24%, 22% and 20% in CY21, CY22, CY23 and H1CY24 respectively. Order inflow for the quarter was INR 34bn, + 11% YoY.

ICICI Securities Limited

Pick of the Week: Abbott India Ltd. - 28 October 2024

Abbott India, a leading pharmaceutical company and subsidiary of Abbott Laboratories, focuses on developing and distributing a diverse range of...

Axis Direct

ABB India (ABB IN) - Stellar Quarter; Outlook Remains Very Robust

Prabhudas Lilladher's research report onABB India We revise our CY24/25E EPS estimates by +16.0%/+21.4% factoring in a robust demand environment...

Prabhudas Lilladhar

Abbott India Ltd - Highest-Ever EBITDA Margins

The compnay achieved higher sales growth on accoutnt of a change in product mix, and a higher share of the antidiabetics, vitamins, and Hormones...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)